Dow Jones
37.851,66 -609,26 (-1,58%) Nasdaq
15.450,69 -262,06 (-1,67%) Nikkei 225
37.628,48 -831,60 (-2,16%) EUR/USD
1,0720 +0,0020 (+0,18%) Bitcoin EUR
59.600,16 -667,42 (-1,11%) CMC Crypto 200
1.377,41 -5,17 (-0,37%)
Cassava Sciences, Inc. (SAVA)
| Chiusura precedente | 20,74 |
| Aperto | 20,58 |
| Denaro | 21,27 x 100 |
| Lettera | 21,42 x 100 |
| Min-Max giorno | 20,43 - 21,64 |
| Intervallo di 52 settimane | 12,32 - 32,10 |
| Volume | |
| Media Volume | 723.427 |
| Capitalizzazione | 922,217M |
| Beta (5 anni mensile) | -0,40 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,32 |
| Prossima data utili | 29 apr 2024 - 03 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 13 dic 2012 |
| Stima target 1A | N/D |
GlobeNewswireStatement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct.Leak of CUNY report preceded by massive increase in short selling. AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzh
- GlobeNewswire
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
CEO to Present on Wednesday, October 11th, at 10:30am ETAUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A live webcast and archived replay will also be available. Live Webcast: https
- GlobeNewswire
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients. AUSTIN, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer’s patients are enrolled in this 12-month trial.
